Publications database

Displaying 91 - 95 of 95

Report on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs

The report assesses the risks of PMMA, especially in association with the already controlled substance PMA (para-methoxyamphetamine). PMMA, is an amphetamine-like substance very close to PMA, and is almost exclusively sold in...

Report on the risk assessment of GHB in the framework of the joint action on new synthetic drugs

Since the mid-1990s, GHB – widely used in human and veterinary medicine for 30 years – has been surfacing as a recreational drug. Some EU countries have reported worries over GHB’s surreptitious...

Report on the risk assessment of ketamine in the framework of the joint action on new synthetic drugs

Since the mid-1990s, ketamine – widely used in human and veterinary medicine for 30 years – has been surfacing as a recreational drug. Concern over ketamine centres on its unpredictability in producing...

Report on the risk assessment of 4-MTA in the framework of the joint action on new synthetic drugs

An enlarged EMCDDA Scientific Committee met from 18–19 May 1999 in Lisbon to assess the risks of the synthetic drug 4-MTA (4-methylthioamphetamine) in the framework of the Joint action on new synthetic...

Report on the risk assessment of MBDB in the framework of the joint action on new synthetic drugs

On 27 February 1998, the drug MBDB (N-methyl-1-(1,3-benzodioxol- 5-yl)-2-butanamine) became the first new synthetic drug to be submitted for risk assessment under the terms of the Joint Action concerning the information exchange...